Osorio, Liseth S.; Ionta, Marisa; Demuner, Antonio J.; de Sousa, Bianca L.; Ferraz, Guilherme O.; Varejao, Eduardo V. V.; Ferreira-Silva, Guilherme A.; Pilau, Eduardo J.; Silva, Evandro; dos Santos, Marcelo H. published an article about the compound: 1-(Bromomethyl)-4-iodobenzene( cas:16004-15-2,SMILESS:IC1=CC=C(CBr)C=C1 ).Formula: C7H6BrI. Aromatic heterocyclic compounds can be classified according to the number of heteroatoms or the size of the ring. The authors also want to convey more information about this compound (cas:16004-15-2) through the article.
In the present study, a series of novel triazole compounds, e.g., I were obtained by conjugation between hydnocarpic acid and functionalized azides via copper(I)-catalyzed azide-alkyne cycloaddition reaction (CuAAC). Hydnocarpic acid and its derivatives were tested against estrogen-pos. breast carcinoma (MCF-7), hepatocellular carcinoma (HepG2), and non-small cell lung cancer (A549) cell lines. The compound I displayed promising antiproliferative activity against A549 cells. It was demonstrated that this compound selectively inhibited the viability of A549 cell cultures. Furthermore, compound I inhibited the clonogenic capacity of A549 cells, and this effect was associated to its ability to inhibit cell cycle progression at G1 phase. These findings indicate that compound I is a promising antitumor agent on A549 cells and support further studies to evaluate the mol. mechanisms underlying its antiproliferative activity. In addition, hydnocarpic acid should be considered as a promising chem. prototype to obtain novel antineoplastic agents.
If you want to learn more about this compound(1-(Bromomethyl)-4-iodobenzene)Formula: C7H6BrI, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(16004-15-2).
Reference:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics